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Abstract  
Background: Serum biomarkers for diagnosis and risk-stratification of childhood solid 
tumors would improve the accuracy and timeliness of diagnosis and reduce the need for 
invasive biopsies. We hypothesized that differential expression and/or release of 
microRNAs by such tumors may be detected as altered serum microRNA profiles. 
Methods: We undertook global quantitative RT-PCR microRNA profiling (n=741) on 
RNA extracted from 53 serum samples, representing 33 diagnostic cases of common 
childhood cancers plus 20 controls. Technical confirmation was performed in a subset of 
21 cases, plus four independent samples. Results: We incorporated robust quality-control 
steps for RNA extraction, qRT-PCR efficiency and hemolysis quantification. We evaluated 
multiple methods to normalize global profiling data and identified that the ‘global-mean’ 
approach was optimal. We generated a panel of six microRNAs that were most stable in 
pediatric serum samples and therefore most suitable for normalization of targeted 
microRNA qRT-PCR data. Tumor-specific serum microRNA profiles were identified for 
each tumor type and selected microRNAs underwent confirmatory testing. We identified a 
panel of microRNAs (miR-124-3p/miR-9-3p/miR-218-5p/miR-490-5p/miR-1538) of 
potential importance in the clinical management of neuroblastoma, as they were 
consistently highly over-expressed in MYCN-amplified high-risk cases (MYCN-NB). We 
also derived candidate microRNA panels for non-invasive differential diagnosis of a liver 
mass (hepatoblastoma vs. combined MYCN-NB/NB), an abdominal mass (Wilms tumor 
vs. combined MYCN-NB/NB), and sarcoma subtypes. Conclusions: This study describes a 
pipeline for robust diagnostic serum microRNA profiling in solid tumors of childhood, and 
has identified candidate microRNA profiles for prospective testing. Impact: We propose a 
new non-invasive method to diagnose childhood solid tumors. 
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Introduction 
Many solid tumors affecting children rely solely on biopsy for diagnosis. Even where 
diagnostic body fluid markers exist (e.g. urinary catecholamines in neuroblastoma), biopsy 
is needed to estimate prognosis, including assessment of MYCN-amplification and 
segmental chromosomal imbalances (1). The identification of novel body fluid tumor 
markers that may allow non-invasive diagnosis or risk stratification in solid tumors of 
childhood would be an important advance. One promising approach is measurement of 
serum microRNA levels. 
 
MicroRNAs are short, non-protein-coding RNAs that post-transcriptionally regulate gene 
expression (2). Importantly, global microRNA profiles have been shown to classify human 
cancer tissues, including pediatric solid tumors (2,3). In pediatric malignant germ cell 
tumors, for example, the miR-371~373 and miR-302/367 clusters are over-expressed in all 
cases, regardless of patient age, histologic subtype or anatomic site (2) and thus may 
represent a universal biomarker of this disease. Packaging of specific microRNAs in 
membrane-bound exosome particles by tumor cells before release into the bloodstream 
allows for their detection in the serum (4). Indeed, we showed that microRNAs from the 
miR-371~373 and miR-302/367 clusters are detectable at high levels in the serum of 
patients at the time of malignant GCT diagnosis, and that levels fall with treatment (4-6), 
findings recently replicated by others (7,8). Importantly, these profiles can detect disease at 
exceptionally low tumor volumes, demonstrating the sensitivity of this approach (6). 
MicroRNAs have many qualities that make them suitable tumor markers for translation 
into clinical practice, including inherent stability and resistance to degradation, even if 
samples are left at room temperature or subjected to multiple freeze-thaw cycles (9). We 
therefore hypothesized that other childhood tumors would be characterized by the release 
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of specific microRNAs into the bloodstream, which would be detectable as an altered 
serum profile compared with control serum samples. 
 
Here, we report the findings of a proof-of-principle study testing this hypothesis. We 
addressed three important questions: whether it was feasible to extract RNA from the 
serum of children in sufficient amounts to undertake global microRNA profiling; whether 
serum housekeeping microRNAs in children would be similar to those described for adults 
and thus suitable for normalization purposes, and whether lists of candidate biomarkers 
could be generated for validation in larger, prospective studies. We undertook global 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) microRNA 
profiling in serum samples taken from patients at the time of diagnosis of common 
childhood cancers (n=33) and compared the results with profiles from age- and gender-
matched pediatric control samples (n=20). We describe in detail the detection and analysis 
pipeline used to make these observations, including highly robust quality control and novel 
normalization steps, essential for translation of these findings into clinical practice. We 
identify profiles specific for each of the 11 types of pediatric solid tumor investigated. In 
particular, we report a panel of serum microRNAs that segregate MYCN-amplified 
International Neuroblastoma Risk Group (INRG) (1) high-risk neuroblastoma from non-
MYCN-amplified INRG low-risk neuroblastoma and other tumors. 
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Materials and Methods 
The study received approval from the Multicenter Research Ethics Committee (reference 
02/4/71) and Local Research Ethics Committee (reference 01/128) and was performed with 
full informed parental consent. All experimental steps were compliant with the Minimum 
Information for Publication of Quantitative Real-time PCR Experiments (MIQE) (10) (see 
Supplementary Materials and Methods). 
 
Patient demographics and tumor types analyzed 
For the main discovery-phase of the project, we initially recruited 34 patients aged 0-16 
years (y) at the time of malignant tumor diagnosis (between April 2010 and June 2013), 
together with a further 20 anonymized samples from a control group of patients without 
malignant disease. Clinico-pathological details are listed in Table 1. The tumor group 
included 18 (53%) male patients and 16 (47%) females with a median age ± standard 
deviation of 63 ± 59 months. There were no significant differences in age between the 
male and female patients within the tumor group (p=0.35; two-tailed unpaired t-test). The 
control group included 11 (55%) male patients and 9 (45%) females with a median age of 
49 ± 53 months. There were no significant differences in age between the male and female 
patients within the control group (p=0.92). There were also no significant differences by 
age between the tumor and control groups (p=0.74). The 34 tumors were from 11 different 
tumor types. They comprised i) four neuroblastomas [two MYCN-amplified INRG high-
risk tumors (MYCN-NB); two non-MYCN-amplified INRG low-risk tumors (NB)]; ii) four 
hepatoblastomas (HB); iii) seven Wilms tumors (WT); iv) seven lymphomas [five cases of 
classical nodular-sclerosing Hodgkin’s disease (HD) and two cases of B-cell non-
Hodgkin’s lymphoma (B-NHL)]; v) six sarcomas [three rhabdomyosarcoma (RMS), two 
Ewings sarcoma (ES), one osteosarcoma (OS)]; vi) one DICER1-mutated pleuropulmonary 
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blastoma (PPB) (11) and vii) five central nervous system tumors (gliomas; three WHO 
2007 grade I, one grade II and one grade III) (Table 1). 
 
For the technical confirmation phase of the study, we used 25 samples. These comprised 
17 representative tumor and four control serum samples from the discovery-phase test set 
(Table 1), plus four independent neuroblastoma serum samples from two MYCN-NB and 
two NB cases. In total, the confirmatory set comprised four MYCN-NB samples, four NB, 
three HB, two WT, two RMS, two B-NHL, two HD, two gliomas and four control samples 
(Table 1). There was no difference in tumor volume between the MYCN-NB and NB 
cases. While all four of the MYCN-NB cases were undifferentiated, the grade of the NB 
cases varied from poorly differentiated to differentiating and ganglio-neuroblastoma (Table 
1). 
 
Data normalization 
For details of sample processing, microRNA qRT-PCR profiling and the extensive quality 
control (QC) steps performed, see Supplementary Materials and Methods. Only a single 
sample (WT-4) failed initial QC; 53 samples (98%) therefore underwent full qRT-PCR 
profiling. In initial work, we compared a number of different data normalization methods 
(12) to define the optimal approach to our global serum microRNA profiling study. We 
assessed: 
a) the global mean method, which used the average Ct value of microRNAs expressed 
in at least one of the 53 samples analyzed, as described (12); 
b) the modified global mean method, which did not take into account other samples in 
the dataset and instead used a sample-specific normalization factor plotted on a linear scale 
(12); 
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c) the modified global mean method of common microRNAs (12), i.e. those microRNAs 
expressed in all 53 samples analyzed; 
d) the ten top-ranking microRNAs identified as most stably expressed in the study by 
geNorm (13); 
e) the ten top-ranking microRNAs identified as most stably expressed in the study by 
NormFinder (14); 
f) the six top-ranking overlapping housekeeping microRNAs identified in both d) and e) 
above; 
g) the four housekeeping microRNAs used for initial QC purposes (hkgsQC), namely 
miR-23a-3p, miR-30c-5p, miR-103a-3p and miR-191-5p; 
h) the two small nucleolar RNAs (snoRNAs), RNU38B and RNU49A, present on the 
Exiqon platform; 
i) the single small nuclear RNA (snRNA) RNU6, present on the platform. Both 
snoRNAs and snRNAs are commonly used for microRNA normalization purposes in tissue 
samples (12). 
 
Statistical analyses for discovery-phase serum microRNA quantification 
Following normalization, we removed miRPlus sequences and microRNAs listed as 
obsolete according to miRBase v20 (June 2013), the most recent version of the online 
microRNA registry (www.mirbase.org/). MicroRNA levels were then quantified using the 
delta Ct method, with fold-change = 2(Tumor Ct – mean ‘other tumor’ samples Ct) and 2(Tumor Ct – mean 
control samples Ct). MicroRNAs that had a ≥2.0 fold-change in expression in the tumor type 
under consideration compared with the mean expression value from a) the control group 
and b) the ‘other tumor’ group (comprising all other tumor samples except those under 
consideration) were called as over-expressed and ranked according to fold-change, as 
described (11). 
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Additional analyses were also performed to increase the stringency of our findings further. 
Firstly, it was necessary for a microRNA to be detected at least 2 Ct values lower in the 
test group compared with the ‘no template control’ (NTC) sample to be included in the 
subsequent data analysis. Secondly, a co-efficient of variation (CV) was calculated for 
each over-expressed microRNA, using the formula CV = standard deviation for that 
microRNA/n, where n was the mean expression value of all microRNAs within that tumor 
type. This step identified the level of variation in microRNA expression within the specific 
tumor type and between the control and ‘other tumor’ group. Thirdly, the Robust Rank 
Aggregate (RRA) method was employed, as described (15). For this analysis, samples 
were processed using the BioConductor package ‘RobustRankAggreg’ in the statistical 
software environment R. This algorithm detected microRNAs that were ranked 
consistently higher than expected under the null hypothesis. This was performed by 
studying the position of each microRNA in the over-expressed list (ranked by fold-change) 
for each specific tumor type, compared with the ‘other tumor’ and control group. A 
significance (p-value) score was subsequently assigned for each gene, which calculated 
how much higher it was positioned in the ranked list than expected by chance, as described 
(15). This p-value was adjusted for multiple testing using a Bonferroni correction and was 
used both for re-ranking the genes and as an indicator of the significance of each gene. 
Adjusted scores of p<0.01 were considered significant. Importantly, the RRA method has 
been used by others in meta-analysis of cancer datasets (16). Differences in serum 
microRNA expression levels between experimental groups were assessed using a two-
tailed t-test (p<0.05 significant). 
 
Serum microRNA qRT-PCR for technical confirmation 
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To maximise sensitivity in the technical confirmation study, cDNA was diluted 1:7.5, 
rather than the standard 1:50 dilution. To ensure robustness for this phase of the study, 
previously extracted RNA from each serum sample was assessed in technical triplicate. 
Each RT product was analyzed by PCR, using the cycling conditions adopted in the 
discovery-phase full profiling study. The means of the three triplicate values for each 
microRNA for each sample were calculated. For this targeted work, following QC analysis 
(Supplementary Materials and Methods), data were normalized using the six top-ranking 
overlapping housekeeping microRNAs identified in the overlap between the geNorm and 
NormFinder methods in the full discovery-phase qRT-PCR profiling study. Differences in 
serum microRNA expression levels between experimental groups were assessed using a 
two-tailed t-test (p<0.05 significant). 
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Results 
QC and normalization 
For full details of the QC steps and the assay pipeline developed, see Supplementary 
Results and Supplementary Figures S1 to S5. In the discovery-phase global qRT-PCR 
profiling study, expression of the four housekeeping microRNAs (17) and their mean raw 
Ct values for all samples were very similar to the levels obtained in our initial QC qRT-
PCR (Figure 1A), and were confirmed by linear regression analysis (p<0.0001). The global 
mean method, using the average Ct value of microRNAs expressed in at least one of the 53 
samples analyzed (n=568), was the optimal normalization approach (Figure 1B) and was 
therefore used in the global profiling study. No additional benefit was identified by using 
either the modified global mean method or the modified global mean method of common 
microRNAs (Figure 1B). Use of the single snRNA RNU6 (U6), or the two snoRNAs 
RNU38B and RNU49A (snoRNAs), whilst often used for normalizing microRNA 
expression in tissue samples (12), were not appropriate methods for normalizing serum 
data, as they resulted in increased technical variation of the data compared with other 
normalization methods (Figure 1B). Assessment of the ten top-ranking microRNAs using 
the geNorm and NormFinder algorithms showed only marginal inferiority to the global 
mean method as a normalization approach. 
 
Normalization using the six top-ranking housekeeping microRNAs out of those that were 
common to the top-ten lists generated using NormFinder and geNorm [namely miR-140-3p 
(chromosomal locus 16q22.1), miR-30b-5p (8q24.22), miR-26a-5p (3p22.2), miR-15b-5p 
(3q25.33), miR-30c-5p (6q13) and miR-191-5p(3p21.31)] (Supplementary Figure S6) also 
performed well in our analysis (Figure 1B). Consequently, these six microRNAs were used 
for normalization purposes for the technical confirmation phase of the study, where only 
selected findings were being explored. All six of these top-ranking housekeeping 
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microRNAs were transcribed from different genomic loci, adding strength to the suitability 
of this panel of microRNAs for normalizing all serum expression data, including from 
adult and pediatric patients. Indeed, five of the six microRNAs were previously reported as 
being abundant and stably expressed in serum and plasma in adult patients (17). 
Furthermore, two of the six microRNAs (miR-30c-5p and miR-191-5p) overlapped with 
the four housekeeping microRNAs used for the initial qRT-PCR QC analyses. It should 
also be noted that the four housekeeping microRNAs used in the initial QC checks 
(hkgsQC) also performed well for normalization purposes in the full discovery-phase 
profiling study (Figure 1B), indicating their suitability for screening serum samples.  
 
Serum microRNAs in different tumor types 
No consistent profile of microRNA over-expression common to all tumor groups was 
identified when compared with the control group. However, for each of the 11 tumor types 
studied, we identified microRNAs that were over-expressed compared with both the cohort 
of other childhood tumors and the control group. The number of such microRNAs ranged 
from 22 to 49 (mean 34), depending on tumor type (Supplementary Tables S1 and S2). 
Using the RRA method, the lists were refined to 16 to 26 (mean 21) serum microRNAs in 
each tumor group (Supplementary Table S1). As the MYCN-NB group had the largest 
coefficient of variance for the delta Ct (miR-23a-3p - miR451a) hemolysis levels 
(Supplementary Figure S1E), we only included microRNAs that were ≥2 fold greater than 
the ‘other tumor’ group and control group in both of the MYCN-NB samples being 
interrogated. This reduced the number of microRNAs called as over-expressed in MYCN-
NB from 96 to 35 (Supplementary Table S1), avoiding identification of serum microRNAs 
that were released from red blood cells rather than being disease-associated. 
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The lists of over-expressed serum microRNAs for each tumor group are shown in 
Supplementary Tables S3 to S13. Selected findings for the individual tumor groups were 
used to generate an expression heatmap (Figure 1C). MicroRNAs for the heatmap were 
chosen based on their overall abundance and potential value in differential diagnosis. For 
two microRNAs (miR-122 and miR-877), the -5p strands were selected rather than the -3p 
strands identified in the global profiling study, due to the greater abundance of the -5p 
strands (18) (Supplementary Figure S7). Ten microRNAs from the heatmap were chosen 
for subsequent validation in the technical confirmation study (shown in italics in Figure 1C 
and listed in Supplementary Table S2), along with the six top-ranking housekeeping 
microRNAs that overlapped in the NormFinder and geNorm lists. In the technical 
confirmation study, the 1:7.5 cDNA dilution increased sensitivity and did not inhibit the 
PCR reaction. As expected, the 16 microRNAs were detected at approximately 3 Ct values 
lower in the 1:7.5 dilutions compared with the 1:50 dilutions (Supplementary Figure S8). 
The suitability of all 25 samples for the technical confirmation study was verified by 
assessment of triplicate UniSp6 values (Supplementary Figure S9A). Expression levels of 
the six housekeeping microRNAs were assessed in technical triplicate and showed high 
consistency (Supplementary Figure S9B). 
 
Taken together, our data strongly suggest important clinical applications based on serum 
microRNA quantification. The most promising are described in the following sections. 
 
MYCN-amplified high-risk neuroblastoma (MYCN-NB) vs. non-MYCN-amplified 
low-risk neuroblastoma (NB). 
Treatment schedules for neuroblastoma rely on distinguishing tumors by the presence or 
absence of INRG high-risk molecular abnormalities, such as MYCN-amplification (1). 
Interestingly, our most striking findings were found in the MYCN-NB group. The five 
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over-expressed serum microRNAs (miR-124-3p, miR-9-3p, miR-218-5p, miR-490-5p and 
miR-1538) that were top-ranking compared with both the ‘other tumor’ group (including 
NB samples) and the controls (Supplementary Table S3) are shown in the heatmap (Figure 
1C, panel 1). Levels of these five microRNAs in individual tumor types in the discovery-
phase test set are highlighted in boxplot analysis (Figure 2A). Significant over-expression 
of all five microRNAs in the MYCN-NB samples versus the ‘other tumor’ group was 
shown in the subsequent confirmatory qRT-PCR experiments, performed in technical 
triplicate (p<0.05 for all comparisons) (Figure 2B). In a focussed ‘differential diagnosis’ 
analysis of the MYCN-NB versus the NB group in the confirmatory study, there was a 
significant difference in expression levels for miR-124-3p and miR-9-3p individually 
(p<0.05) (Figure 2C). In addition, in the technical confirmation set, the panel of all five 
microRNAs successfully distinguished MYCN-NB from NB samples (p=0.031) (Figure 
2C). 
 
Hepatoblastoma (HB) vs. all neuroblastomas (MYCN-NB/NB). 
In children presenting with a liver tumor/enlargement, it may be important to distinguish a 
primary lesion, such as HB, from involvement by a tumor from elsewhere e.g. 
neuroblastoma. For HB, of the 49 over-expressed serum microRNAs, miR-483-3p, miR-
122-3p and miR-205-5p were ranked in the top ten by fold-change (Supplementary Table 
S5), with similar fold-changes versus the controls and ‘other tumor’ group. Due to its 
greater abundance (Supplementary Figure S7) (18), miR-122-5p, rather than miR-122-3p, 
was selected for confirmatory testing along with miR-483-3p and miR-205-5p (Figure 1C, 
panel 2). The findings for these three microRNAs in individual tumor types in the 
discovery-phase test set are highlighted by boxplot analysis (Figure 3A). Significant over-
expression of each of the three microRNAs in the HB group was verified in the technical 
confirmation study, versus both the ‘other tumor’ group (which included all eight MYCN-
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NB/NB samples, two of which showed liver involvement) and the control group (p<0.05 
for all comparisons) (Figure 3B). For the neuroblastomas, there was no association 
between liver involvement and greater abundance of the HB-associated microRNAs. It was 
however noted that levels of the liver-specific miR-122-5p (19) were occasionally 
increased in non-HB samples, for example, in a case of pancreatic RMS presenting with 
obstructive jaundice (RMS-2) (Figure 3B). Accordingly, miR-122-5p needed to be a part 
of a larger panel to ensure sufficient specificity for HB. In focussed ‘differential diagnosis’ 
plots for the HB group versus the combined MYCN-NB/NB group, all three microRNAs 
were individually significantly elevated in HB (p<0.05 for all comparisons) (Figure 3C). 
Furthermore, the three microRNA panel also distinguished HB from MYCN-NB/NB 
(p=0.0001) (Figure 3C). 
 
Wilms tumor (WT) vs. all neuroblastomas (MYCN-NB/NB).  
Due to their anatomical proximity, it may be difficult both clinically and radiologically to 
distinguish WT from neuroblastoma; indeed, some neuroblastomas may be intra-renal (20, 
21). Due to the different management and prognosis of these two tumor types, it is 
important to differentiate them diagnostically (21). We screened our profiling data from 
the discovery-phase test set for microRNAs that might be informative in this differential 
diagnosis setting. We identified miR-129-5p (over-expressed in both the MYCN-NB and 
NB lists; Supplementary Tables S3 and S4, respectively) and miR-143-3p (10.7 greater 
fold-change in levels in WT compared with the combined MYCN-NB/NB samples; data 
not shown) for subsequent testing (Figure 1C, panel 4 and Figure 4A). The technical 
confirmation study established that miR-143-3p was increased in WT compared with the 
‘other tumor’ group (p=0.003), with miR-129-5p being over-expressed in the majority of 
MYCN-NB/NB cases (Figure 4B). In ‘differential diagnosis’ plots, miR-143-3p 
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distinguished WT from MYCN-NB/NB (p=0.0005), with miR-129-5p being over-
expressed in six of eight MYCN-NB/NB cases versus WT (Figure 4C). 
 
Sarcoma differential diagnosis 
Sarcomas may present with bone lesions (ES/OS), soft tissue masses (RMS/ES), or both 
(ES). Consequently, discriminating these tumors is important, but may be challenging. 
Serum microRNAs that were over-expressed for RMS, ES and OS are listed in 
Supplementary Tables S7-S9, respectively. Overall levels of representative microRNAs 
specific for RMS, ES and OS versus the other sarcoma subtypes are illustrated in Figure 
1C, (panels 5-7, respectively). In particular, overall analysis (Figure 5A) and ‘differential 
diagnosis’ plots of the global profiling data (i.e. discovery-phase test set) (Figure 5B) 
showed that miR-214-3p, miR-214-5p and miR-92b-3p individually segregated ES from 
RMS/OS (p<0.05 for all comparisons), as did the three microRNA panel (p=0.0098) 
(Figure 5B). For OS, miR-500a-5p, miR-512-5p and miR-519a-3p showed much higher 
serum expression than other tumors, including ES (Supplementary Figure S10). 
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Discussion 
We report a robust, quality controlled pipeline suitable for quantifying serum microRNA 
levels in pediatric patient cohorts (and potentially adult samples), including the assessment 
of RNA extraction, degree of sample hemolysis and qRT-PCR efficiency. The described 
approach minimizes technical alterations and maximizes true biological variation between 
samples, to allow identification of lists of over-expressed serum microRNAs between 
study groups, as exemplified here for common solid tumors of childhood. We assessed 
multiple normalization approaches and identified that for high-throughput global serum 
microRNA qRT-PCR data, the ‘global mean’ method (12) was optimal. In addition, we 
generated a panel of six housekeeping microRNAs that were most stable in pediatric serum 
samples and therefore suitable for normalizing qRT-PCR data in more targeted low-
throughput studies. Interestingly, the six microRNAs showed substantial overlap with 
findings from adult samples (17). 
 
The most striking tumor findings were for MYCN-amplified high-risk neuroblastoma 
(MYCN-NB). The blood-based microRNA panel identified here has clinical relevance, due 
to the current requirement for surgical biopsy to confirm the diagnosis and look for INRG 
high-risk genomic changes, such as MYCN-amplification (1). Very recently, qRT-PCR 
detection of neuroblastoma-specific messenger RNAs (mRNAs) in peripheral blood from 
children at diagnosis of advanced stage neuroblastoma have been reported, with high levels 
of TH and PHOXB2 representing clinically useful biomarkers of risk (22). However, 
potential blood-based mRNA biomarkers can be subject to considerable variation in levels 
for technical as well as biological reasons (23,24). In particular, mRNAs are inherently 
unstable at room temperature and rapidly degrade in blood samples that are not stored cor-
rectly (23, 24). In contrast, serum microRNAs offer particular advantages as blood-based 
biomarkers as they are not prone to such technical variations (9). 
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The MYCN-NB-specific serum microRNAs identified here are of biological relevance. It 
has been known for some time that MYCN amplification status of neuroblastoma tissue 
samples determines global microRNA profiles (25) and our findings are in keeping with 
this observation. MiR-124-3p is the most abundant neuronal-specific microRNA and 
silencing of miR-124 in neuroblastoma cells in vitro resulted in their differentiation (26). 
In addition, expression of miR-9 is activated by MYCN protein, which directly binds to the 
promoter region of this microRNA (27). In neuroblastoma tissues, high miR-9 levels 
correlated with MYCN-amplification, tumor grade and metastatic status (27). 
 
Other tumor-specific serum microRNAs are of biological relevance. For example, miR-122 
is highly abundant in liver tissues and is considered liver-specific. Recently, reduced miR-
122 expression has been shown in HB compared with normal liver tissue (28). Here, we 
found elevated serum levels of miR-122-5p in HB samples compared with other tumors 
and controls. Down-regulation of miR-122 in HB (compared with normal liver tissue) (28), 
but detection at elevated levels in the serum of HB patients is consistent with other 
observations (11). Passive leakage of microRNAs from tumor cells into the bloodstream, 
due to abnormal cellular function, may account for these findings. Alternatively, there may 
be active and selective microRNA release mechanisms from tumor cells, which may 
subsequently promote an environment suitable for tumor cell growth and metastasis (11). It 
should be noted that miR-122 is a general non-specific marker of liver injury, and is 
increased in the serum in jaundiced patients, for example (29). Therefore, a wider panel of 
serum microRNAs, as identified in this study, is likely to offer increased specificity for HB 
compared with other tumors and disease states. Of note, one of the additional microRNAs, 
in the panel that we identified, miR-205, has been shown contribute to hepatocyte 
differentiation (30). 
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The serum panel for Wilms tumor (WT) included miR-141-5p, which has been reported to 
be abundant in normal mature renal tissue and down-regulated in WT (31). The elevated 
serum miR-141-5p levels at diagnosis in WT patients are likely to be due to the same 
cellular microRNA release mechanisms suggested for miR-122-5p in HB above. For RMS, 
serum levels of miR-183-5p were elevated at diagnosis. This is consistent with over-
expression of miR-183-5p in RMS tissues, leading to down-regulation of the tumor 
suppressor transcription factor EGR1 and increased cell migration (32). For osteosarcoma 
(OS), seven of the 44 (16%) over-expressed serum microRNAs were from the large 
microRNA cluster on chromosome 19, at 19q13, termed C19MC, including miR-512-5p 
and miR-519a-3p. Serum levels of these microRNAs were very low indeed in other tumor 
groups and control samples. Interestingly, genomic amplification at 19q13 occurs 
frequently in OS and may account for these findings (33). 
 
Our detection of a panel of differentially expressed serum microRNAs in central nervous 
system gliomas (GL) (Supplementary Table S13) is likely to reflect disturbance of the 
blood brain barrier, allowing transfer of microRNAs into the bloodstream. Indeed, similar 
findings have been reported recently (34). The serum GL panel included miR-155-5p and 
miR-124-3p. In GL tissues, miR-155 levels were noted to be higher than in normal brain, 
associated with higher pathological grade and poor clinical outcomes, revealing miR-155 
expression as a potential independent prognostic factor and therapeutic target for human 
glioma (35). Furthermore, in a study investigating altered microRNA expression during 
GL malignant transformation, both miR-155-5p (increased) and miR-124-3p (decreased) 
showed altered expression between GL stem cells and neural stem cells (36). Interestingly, 
apart from MYCN-NB samples, the GL group was the only other in which we could detect 
miR-124-3p in the serum (Figure 2, panel 1). MiR-124-3p is under-expressed in pediatric 
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GL (pilocytic astrocytoma) compared with non-neoplastic brain tissue (37), and again 
detection in the serum is likely due to active release or passive leak of miR-124-3p from 
the GL tumor cells across the disrupted blood brain barrier. 
 
As the number of samples assessed for each of the tumor subtypes is small in the present 
proof-of-principle study, it will be important to confirm our findings in larger, prospective 
investigations. The fact that the panel of serum microRNAs that distinguished the initial 
group (n=4) of MYCN-NB from NB patients was confirmed in a small independent panel 
of patient samples (n=4) highlights that these changes are promising and worthy of further 
testing. If confirmed in future studies, we propose that the panels of childhood solid tumor-
associated microRNAs identified here represent useful candidate biomarkers for improving 
the accuracy of pediatric cancer diagnosis. Such markers may reduce or obviate the need 
for diagnostic histological biopsy and the associated risks of anaesthesia and surgery. 
Furthermore, compared with the labor-intensive diagnostic techniques in current clinical 
use, a qRT-PCR approach, based on the analysis pipeline reported here, is likely to be 
more cost-effective, thereby offering health economic as well as clinical benefits. 
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Table 1. Clinico-pathological characteristics of the patients in the tumor and 
control groups. The gender, age, cancer type of the patients and which samples were 
used in the confirmatory study are listed. Key: MYCN-NB=MYCN-amplified high-
risk neuroblastoma (n=4 samples), NB=non-MYCN-amplified low-risk neuroblastoma 
(n=4), HB=hepatoblastoma (n=4), WT=Wilms tumor (n=6), 
Sample Code Gender Age (mo) Cancer Type Additional Comments Confirmatory Study 
1 MYCN-NB-1 M 98 MYCN-amplified HR neuroblastoma Undifferentiated   
2 MYCN-NB-2 M 6 MYCN-amplified HR neuroblastoma Undifferentiated   
3 NB-1 M 67 LR neuroblastoma Ganglio-neuroblastoma   
4 NB-2 F 21 LR neuroblastoma Differentiating   
5 HB-1 M 14 Hepatoblastoma Mixed fetal and embryonal type histology   
6 HB-2 M 85 Hepatoblastoma Mixed fetal and embryonal type histology   
7 HB-3 F 25 Hepatoblastoma Fetal type histology  
8 HB-4 F 14 Hepatoblastoma Fetal type histology   
9 WT-1 F 54 Wilms tumor Biopsy - anaplastic histology   
10 WT-2 M 22 Wilms tumor Biopsy -stromal type histology; WAGR    
11 WT-3 F 12 Wilms tumor Biopsy - mixed type histology  
12 WT-4 F 25 Wilms tumor Biopsy - triphasic histology. Failed QC.  
13 WT-5 M 41 Wilms tumor Bilateral tumors  
14 WT-6 F 16 Wilms tumor Biopsy - stromal type histology  
15 WT-7 F 97 Wilms tumor Biopsy - triphasic histology  
16 RMS-1 M 121 Rhabdomyosarcoma Abdominal   
17 RMS-2 M 52 Rhabdomyosarcoma Pancreatic site; jaundiced; embryonal type  
18 RMS-3 F 104 Rhabdomyosarcoma Nasopharyngeal site; embryonal type   
19 ES-1 M 152 Ewings sarcoma Bone and soft tissue of cervical vertebrae  
20 ES-2 M 34 Ewings sarcoma Soft tissue of lumbo-sacral region  
21 OS-1 F 103 Osteosarcoma Previous RMS/Li Fraumeni syndrome  
22 NHL-1 M 176 B-cell non-Hodgkin’s lymphoma  Burkitt’s lymphoma   
23 NHL-2 M 110 B-cell non-Hodgkin’s lymphoma Burkitt’s lymphoma   
24 HD-1 F 186 Hodgkin’s disease Classical, nodular sclerosing subtype  
25 HD-2 M 156 Hodgkin’s disease Classical, nodular sclerosing subtype   
26 HD-3 M 176 Hodgkin’s disease Classical, nodular sclerosing subtype   
27 HD-4 F 159 Hodgkin’s disease Classical, nodular sclerosing subtype  
28 HD-5 F 172 Hodgkin’s disease Classical, nodular sclerosing subtype  
29 PPB-1 F 133 Pleuropulmonary blastoma Germline DICER1 mutation  
30 GL-1 M 53 Central nervous system glioma Pilocytic astrocytoma WHO 2007 grade I   
31 GL-2 F 68 Central nervous system glioma Pilocytic astrocytoma WHO 2007 grade I  
32 GL-3 M 172 Central nervous system glioma Gliomatosis cerebri, WHO 2007 grade III  
33 GL-4 F 17 Central nervous system glioma Oligodendroglioma WHO 2007 grade II  
34 GL-5 M 59 Central nervous system glioma Pilocytic astrocytoma WHO 2007 grade I   
       
35 MYCN-NB-3 F 17 MYCN-amplified HR neuroblastoma Undifferentiated; abdominal   
36 MYCN-NB-4 M 32 MYCN-amplified HR neuroblastoma Undifferentiated; abdominal   
37 NB-3 M 5 LR neuroblastoma Poorly differentiated   
38 NB-4 M 3 LR neuroblastoma Poorly differentiated   
       
39 C-1 F 38 N/A N/A  
40 C-2 M 159 N/A N/A  
41 C-3 F 34 N/A N/A   
42 C-4 F 142 N/A N/A   
43 C-5 F 129 N/A N/A  
44 C-6 M 23 N/A N/A  
45 C-7 F 21 N/A N/A  
46 C-8 M 57 N/A N/A  
47 C-9 M 34 N/A N/A  
48 C-10 F 38 N/A N/A   
49 C-11 M 134 N/A N/A  
50 C-12 M 48 N/A N/A  
51 C-13 M 74 N/A N/A  
52 C-14 F 140 N/A N/A  
53 C-15 M 181 N/A N/A  
54 C-16 M 29 N/A N/A  
55 C-17 M 26 N/A N/A  
56 C-18 F 50 N/A N/A  
57 C-19 M 36 N/A N/A   
58 C-20 F 86 N/A N/A  
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RMS=rhabdomyosarcoma (n=3), ES=Ewing’s sarcoma (n=2), OS=osteosarcoma 
(n=1), B-NHL=B-cell non-Hodgkin’s lymphoma (n=2), HD=Hodgkin’s disease 
(n=5), PPB=pleuropulmonary blastoma (n=1), GL=Central nervous system glioma 
(n=5), C=control samples (n=20). HR= high-risk; LR= low-risk. Samples 1-34 and 
39-58 were used in the discovery-phase global profiling study, while samples 35-38 
were used in the technical confirmation study. 
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Figure Legends 
Figure 1. Discovery-phase global qRT-PCR profiling. A) Comparison of serum 
housekeeping microRNA expression in the initial QC and full qRT-PCR analyses. 
The graph shows the mean raw Ct values (y-axis) of the four housekeeping 
microRNAs (miR-23a-3p, miR-30c-5p, miR-103a-3p, and miR-191-5p) in the initial 
QC and full qRT-PCR run for each of the 53 samples (x-axis) taken forward for full 
analysis. Key: QC = quality control; HK = housekeeping. For tumor abbreviations 
please refer to Table 1. B) Assessment of normalization approaches for global 
microRNA profiling in serum samples from pediatric cancer patients and controls. 
The graph shows the cumulative distribution of serum microRNA expression (y-axis) 
plotted against the standard deviation (x-axis) for all 53 samples in the cohort for nine 
different normalization approaches (identified by the color key). Normalization key: 
hkgsQC = using the four housekeeping microRNAs used in the initial QC screening 
in A) above; snoRNAs = using the two snoRNAs on the qRT-PCR platform and U6 = 
using the single small nuclear RNA RNU6 on the platform. C) Heatmap showing 
overall expression levels of selected serum microRNAs identified by global qRT-PCR 
profiling. Columns represent each individual tumor type or the control group. Each 
row represents the mean normalized serum expression level for the listed microRNA 
(global mean method), using log2 Ct values across each tumor type or control group. 
Key: Selected serum microRNA signature for: panel 1=MYCN-NB vs. NB; 2=HB vs. 
MYCN-NB/NB; 3=WT; 4=MYCN-NB/NB vs. WT; 5/6/7=RMS, ES and OS, 
respectively, vs. the other two sarcoma subtypes; 8=HD vs. B-NHL; 9=PPB; 
10=glioma. For tumor abbreviations see Table 1. Italicized microRNAs were those 
used for the technical confirmation study. Red=microRNA over-expression; 
blue=microRNA under-expression. 
 
Serum microRNAs in childhood tumors 
 29
Figure 2. Serum microRNA expression in MYCN-amplified high-risk 
neuroblastoma (MYCN-NB). A) The boxplots show the median (black bar) and 
inter-quartile range (dark blue bar) raw Ct values (y-axis) of five highly over-
expressed microRNAs in MYCN-NB (miR-124-3p, miR-9-3p, miR-218-5p, miR-
490-5p and miR-1538) relative to other tumors and controls, across the 53 samples in 
the global qRT-PCR profiling study (discovery-phase test set). Whiskers represent 
1.5x inter-quartile range. Dots represent outlier samples. B) The graphs show the 
mean normalized relative expression values (horizontal bars) and SEM (vertical bars) 
for the microRNAs listed in A) above, in MYCN-NB samples versus ‘other tumor’ 
and control samples, in the confirmatory qRT-PCR study. C) The ‘differential 
diagnosis’ graphs show the mean normalized relative expression values for miR-124-
3p and miR-9-3p in MYCN-NB samples versus NB samples, in the technical 
confirmation qRT-PCR study. In addition, an overall mean-adjusted relative 
expression value for the specific five microRNA panel was calculated, where each of 
the five microRNAs listed in A) above was given an equal weighting. Confirmatory 
qRT-PCR data were normalized to the six top-ranking housekeeping microRNAs 
identified using geNorm and NormFinder (Supplementary Figure S6), and are shown 
relative to the mean expression levels in the control group. Error bars=standard error 
of the mean (SEM). For tumor abbreviations see Table 1. 
 
Figure 3. Serum microRNA expression in hepatoblastoma (HB) vs. all 
neuroblastomas (MYCN-NB/NB). A) The boxplots show the median (black bar) and 
inter-quartile range (light green bar) raw Ct values (y-axis) of three highly over-
expressed microRNAs in HB (miR-483-3p, miR-205-5p and miR-122-5p) relative to 
other tumors and controls, across the 53 samples in the full qRT-PCR study 
(discovery-phase test set). Whiskers represent 1.5x inter-quartile range. Dots 
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represent outlier samples. B) The graphs show the mean normalized relative 
expression values (horizontal bars) and SEM (vertical bars) for the microRNAs listed 
in A) above, in HB samples versus the ‘other tumors’ and control samples, in the 
confirmatory qRT-PCR study. C) The ‘differential diagnosis’ graphs show the mean 
normalized relative expression values for the microRNAs listed in A) above, in 
MYCN-NB samples versus NB samples, in the technical confirmation qRT-PCR 
study. In addition, an overall mean-adjusted relative expression value for the specific 
three microRNA panel was calculated, where each of the three microRNAs listed in 
A) above was given an equal weighting. Confirmatory qRT-PCR data were 
normalized and plotted as described in Figure 2. Error bars=SEM. For tumor 
abbreviations see Table 1. 
 
Figure 4. Serum microRNA expression in Wilms tumor (WT) vs. all 
neuroblastomas (MYCN-NB/NB). A) The boxplots show the median (black bar) and 
inter-quartile range (colored bar) raw Ct values (y-axis) of two microRNAs (miR-129-
5p and miR-143-3p) relative to other tumors and controls, across the 53 samples in 
the full qRT-PCR study (discovery-phase test set). Whiskers represent 1.5x inter-
quartile range. Dots represent outlier samples. B) and C) The graphs show the mean 
normalized relative expression values (horizontal bars) and SEM (vertical bars) in 
MYCN-NB/NB (miR-129-5p) or WT (miR-143-3p) samples versus B) ‘other tumors’ 
and control samples or C) each other, in ‘differential diagnosis’ plots, in the technical 
confirmation qRT-PCR study. Confirmatory qRT-PCR data were normalized and 
plotted as described in Figure 2. Error bars=SEM. For tumor abbreviations see Table 
1. 
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Figure 5. Serum microRNA expression in sarcoma subtypes. A) The boxplots 
show the median (black bar) and inter-quartile range (pink bar) raw Ct values (y-axis) 
of three selected microRNAs (miR-214-3p, miR-214-5p and miR-92b-3p) in ES 
(Ewings sarcoma) samples compared with other sarcoma samples [OS (osteosarcoma) 
and RMS (rhabdomyosarcoma)], across the 53 samples in the full qRT-PCR study 
(discovery-phase test set). Whiskers represent 1.5x inter-quartile range. Dots 
represent outlier samples. B) ‘Differential diagnosis’ plots for ES vs. RMS/OS in the 
full qRT-PCR study (discovery-phase test set). Data were normalized using the global 
mean method and are relative to the mean expression levels in the control group. In 
addition, an overall mean-adjusted relative expression value for the specific three 
microRNA panel was calculated, where each of the three microRNAs listed in A) 
above was given an equal weighting. Error bars=SEM. For tumor abbreviations see 
Table 1. 
 





